Table 32. Patient characteristics–chlorpromazine versus quetiapine

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Peuskens et al. 1997**121 | ***Study design:*** RCT  ***Registration #:*** NR  ***Study population:*** Schizophrenia  ***DSM Classification:*** DSM–III–R  ***Study period:*** NR  ***Number of centers:*** Multicenter(n = 28)  ***Setting:*** Inpatient  ***Country:*** Belgium, UK, Spain, France, South Africa  ***Financial support:*** Industry (Zeneca)  ***Washout period performed:*** yes (24 h)  ***Run-in phase performed:*** no  ***Followup period:*** 6 wks | ***Main inclusion criteria:*** Age 18–65; acute exacerbation of chronic or subchronic Sz, or schizophreniform disorder; BPRS score = 27; BPRS pos score = 3 on two or more of 'conceptual disorganization', 'suspiciousness', 'hallucinatory behavior' and 'unusual thought content'; a score of = 4 on CGI–S.  ***Main exclusion criteria:*** Any medical condition or laboratory abnormality that might confound the trial results; had received long–acting depot medication; had participated in another investigational drug trial during the 4 wks prior to randomization; evidence of significant alcohol or other drug abuse within the previous 12 mo. | ***G1:***  ***Age (mean±SD):*** 34.00±11.00  ***Males (n(%)):*** *66*/100 (66%)  ***Ethnicity:*** Caucasian 80/100(80%)  ***BL symptom scores:*** BPRS (mean±SD): 44±11  PANSS (mean±SD): 27.8±8  ***G2:***  ***Age (mean±SD):*** 32.00±10.00  ***Males (n(%)):*** 63/101 (62.4%)  ***Ethnicity:*** Caucasian 81/101 (80.2%)  ***BL symptom scores:*** BPRS (mean±SD): 46±10  PANSS (mean±SD): 28±8 | ***G1:***  ***Classification:*** FGA  ***Drug:*** Chlorpromazine  ***Dosage:*** 75–750mg/d  ***Intervals:*** TID  ***G2:***  ***Classification:*** SGA  ***Drug:*** Quetiapine  ***Dosage:*** 75–750mg/d  ***Intervals:*** TID |

AP = antipsychotic; BL = baseline; BPRS = Brief Psychiatric Rating Scale; CGI = Clinical Global Impressions; d = day; DSM = Diagnostic and Statistical Manual of Mental Disorders; FGA = first-generation antipsychotic; mg = milligram; mo = month; n = number; NA = not applicable; NR = not reported; PANSS  = Positive and Negative Syndrome Scale; pts = patients; RCT = randomized controlled trial; SD = standard deviation; SGA = second-generation antipsychotic; Sz = schizophrenia; TID = Three times daily; Tx = treatment; wk = week; yr = year